SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic,castrate-refractory prostate cancer (mCRPC)—A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group.
Robert J. Jones(Beatson West of Scotland Cancer Centre), Simon J. Crabb(University of Southampton), John Staffurth(Velindre NHS Trust), Amit Bahl(At Bristol), Jonathan Tugwood(Cancer Research UK), Charlotte Westbury(Institute of Cancer Research), Elaine McCartney(Cancer Research UK), Caroline Kelly(Cancer Research UK), Chantévy Pou(University of Glasgow), Christy Ralph(University of Leeds), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Tony Elliott(The Christie Hospital), Fiona Thomson(University of Glasgow), Alison Birtle(University of Lancashire), Karen Morris(Cancer Research UK Manchester Institute), Balaji Venugopal(Beatson West of Scotland Cancer Centre), Andrew Protheroe(Churchill Hospital), Laura Divers(Cancer Research UK), C. A. Hopkins(University of Glasgow), Angus Robinson(Royal Sussex County Hospital)
Cited by 3
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k